pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
Sanofi ($SNY) · news · pharmadog
← back to Sanofi
News mentioning $SNY
149
stories
10h
Scribe’s early-stage IPO standout defies biotech’s derisking trend
biospace
18h
7 biopharma M&A deals where layoffs followed
biospace
1d
11 companies hiring in New Jersey
biospace
2d
STAT+: Doritos as farm-to-table snacks? Big Food, under duress, gets creative
stat
3d
STAT+: Sanofi to lay off 229 workers in Mass., a year after $9.1B Blueprint Medicines acquisition
stat
3d
Regeneron ends eye disease trial for anti-CD3 antibody following safety review
fiercebiotech
6d
STAT+: Pharmalittle: We’re reading about a lawsuit over lab tests for meds, a Bristol myeloma drug, and more
stat
6d
Capricor shares spike on CEO comments; Cytokinetics sues Bristol Myers
biopharma dive
6d
STAT+: Drug-testing lab that has sparked controversy sues group that develops drug standards over criticism
stat
7d
STAT+: Commure terminates payments under its customer referral programs tied to AI products
stat
7d
STAT+: Pharmalittle: We’re reading about California insulin sales, a Moderna patent battle, and more
stat
7d
Zealand sells its rights to Takeda’s blood cancer drug for $100M ahead of FDA approval decision
fiercebiotech
8d
STAT+: Pharmalittle: We’re reading about Lilly ‘black market’ lawsuits, pushback over Trump vaccine plan, and more
stat
8d
Boulevard starts up with $65M to pursue targeted autoimmune drugs
biopharma dive
8d
With tech backing, AI biotechs force biopharma into ‘fail-fast’ drug development
biospace
9d
STAT+: Pharmalittle: We’re reading about an FDA rejection, 340B court battles, and more
stat
9d
Epicrispr, Infinimmune snag combined $165M in VC cash
biospace
9d
Epicrispr lands $90M to advance epigenetic editing drug for rare muscle disease
biopharma dive
9d
Epicrispr raises $90M to rewrite treatment of rare muscle disease
fiercebiotech
10d
STAT+: Pharmalittle: We’re reading about a Sanofi drug shortage, a Jazz Pharma deal, and more
stat
10d
Sobi pens $580M deal for Innate’s skin cancer drug ahead of phase 3 push
fiercebiotech
11d
STAT+: A shortage of two Sanofi medicines for Pompe disease rattles patients
stat
14d
Chutes & Ladders—BioNTech brings in Sobi CEO
fiercebiotech
14d
Braveheart pumps more life into biotech IPO market with $382M expected debut
biospace
14d
Sanofi pauses mid-stage lung study amid new CEO’s ‘rigorous portfolio prioritization’
biospace
14d
The top 12 companies hiring in biopharma now
biospace
15d
Attovia adds to biotech IPO momentum with $289M offering
biopharma dive
15d
Sanofi suspends chronic lung disease phase 2 study, tied to ‘strategic business reasons’
fiercebiotech
15d
A COPD drug from China draws $115M in venture funding
biopharma dive
15d
Lilly drops another gene therapy trial from $1B Prevail buyout
fiercebiotech
← prev
page 1 of 5
next →
